Innovative drug R&D in China

Nature Reviews Drug Discovery

Volumn 10, Issue 5, 2011, Pages 333-334

  Qi, Jingzong ^a   Wang, Qingli ^b   Yu, Zhenhang ^c   Chen, Xin ^a   Wang, Fengshan ^d  

^a FusoGen Pharmaceuticals   (China)

^b CENTER FOR DRUG EVALUATION   (China)

^c China National Center for Biotechnology Development   (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AILDENAFIL; ALBUVIRTIDE; ALPHA2A INTERFERON; BUAGAFURAN; CHIDAMIDE; CHIGLITAZAR; CITRICPLATIN; CYMIPRISTONE; ETHASELEN; GROWTH HORMONE; ICOTINIB; INTERFERON; IPTAKALIM; NEMONOXACIN; NOVAFERON; PEG RHARGINASE; RECOMBINANT HUMAN ARGINASE; RECOMBINANT SUPER COMPOUND INTERFERON; SIFUVIRTIDE; SULCARDINE; THIENORPHINE; TRANTINTEROL; TRICHOSANTHIN; TRIPTOLIDE; TYROSERVATIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y SHAPE BRANCHED POLYETHYLENE GLYCOL RECOMBINANT HUMAN GROWTH HORMONE;

CHINA; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG PROGRAM; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

CHINA; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; HUMANS; RESEARCH; RESEARCH SUPPORT AS TOPIC;

EID: 79955604573     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3435     Document Type: Short Survey

References (1)

1. IMS Intelligence Applied. IMS Health forecasts global pharmaceutical market growth of 5-7 percent in 2011, reaching $880 billion. IMS website [online], http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= 119717f27128b210VgnVCM100000ed152ca2RCRD&cpsextcurrchannel=1 (2010).